[Intravitreal ranibizumab for choroidal neovascularisation associated with adult-onset vitelliform dystrophy].

Abstract

CASE REPORT:

A 70-year-old male patient diagnosed with bilateral adult-onset vitelliform dystrophy presented with a sudden decrease of vision in his left eye associated with the appearance of an occult type of neovascular membrane. It was treated with intravitreal ranibizumab due to juxtafoveal location of the membrane. Two injections were needed to induce total regression of the lesion.

DISCUSSION:

Intravitreal ranibizumab may be effective to induce morphological and functional improvement in cases of choroidal neovascularization secondary to adult-onset vitelliform foveomacular dystrophy. Further case series are required to confirm this observation.

• Authors: E Prieto-Calvo, C Torrón-Fernández Blanco, C Egea-Estopiñán, N Güerri-Monclús, E Ferrer-Novella, O Ruiz-Moreno, L E Pablo-Julvez
• Journal: Archivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 87 Issue 5 Pg. 149-52 (May 2012) ISSN: 1989-7286 [Electronic] Spain
• Vernacular Title: Ranibizumab intravítreo en neovascularización coroidea secundaria a distrofia foveomacular viteliforme del adulto.
• PMID: 22554558 (Publication Type: Case Reports, English Abstract, Journal Article)
• Copyright: Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Ranibizumab

Topics

• Aged
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Choroidal Neovascularization (diagnosis, drug therapy, etiology)
• Humans
• Intravitreal Injections
• Male
• Ranibizumab
• Tomography, Optical Coherence
• Vitelliform Macular Dystrophy (complications)